je.st
news
Tag: inhibitor
Probiodrug Transfers its CDK9 Inhibitor Program to AstraZeneca
2014-01-03 11:53:31| Biotech - Topix.net
Probiodrug AG announced today the transfer of its experimental cyclin-dependent kinase 9 inhibitor program to AstraZeneca .
Tags: program
transfers
inhibitor
astrazeneca
Reckitt Patents Glassware Corrosion Inhibitor
2013-11-04 06:00:00| Happi Breaking News
Tags: patents
inhibitor
corrosion
glassware
Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer
2013-09-11 09:15:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. & LONDON WHITEHOUSE STATION, N.J. & LONDON--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and AstraZeneca (NYSE: AZN) today announced a worldwide licensing agreement for Mercks oral small molecule inhibitor of WEE1 kinase (MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical studies in combination with standard-of-care therapies for the treatment of patients with certain types of ovarian cancer. Language: English Contact: MerckMedia:Caroline Lappetito, (267) 305-7639orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: for
enter
agreement
license
Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimers Disease
2013-07-14 14:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Merck, known as MSD outside the United States and Canada, today announced the presentation of results from a Phase Ib study showing a dose-dependent decrease in amyloid levels in cerebral spinal fluid (CSF) following administration of MK-8931, Mercks investigational oral -site amyloid precursor protein cleaving enzyme (BACE1 or secretase) inhibitor, in patients with mild to moderate Alzheimers disease (AD). In the study, amyloid levels were analyzed as a measure of BACE activity. Language: English Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
study
phase
disease
Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress
2013-04-23 12:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. MK-5172 is an investigational, once-daily, oral HCV NS3/4A protease inhibitor that in preclinical evaluations has demonstrated a high barrier to resistance. Language: English Contact HTML: MerckMedia Contact:Caroline Lappetito, 267-305-7639orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
international
updated